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Abstract
Background: Pre-vaccination information on HPV type-specific prevalence in target populations is essential for
designing and monitoring immunization strategies for cervical cancer (CC) prevention. Data on HPV prevalence in
Italy are available for women over the age of 24 years, target of the population-based CC screening programmes;
while data of HPV prevalence in younger ages are very limited. The present study enrolled Italian women aged 18–
26 years in order to assess the prevalence and distribution of high-risk (HR) HPV types. Risk-factors correlated with
HR-HPV positivity were also described.
Methods: A sample of 2,289 women was randomly selected from the resident population lists of ten Local Health
Units (LHUs) located in six Italian Regions scattered across the country; both rural and urban LHUs were involved.
Women aged between 18 and 26 years and living in the selected LHUs were included in the study; pregnant
women and women who did not speak Italian were excluded. A total of 1,102 women met the inclusion criteria
and agreed to participate. Participants were offered pap test and Hybrid-Capture 2 (HC2) test for HR-HPV types and
genotyping was performed on positive smears.
Results: Out of 1,094 valid samples, 205 (18.7%) were HR-HPV positive. Women with 2–4 (ORadj = 4.15, 95%CI: 2.56-
6.72) and ≥5 lifetime partners (ORadj = 10.63, 95%CI: 6.16-18.36) and women who have used any contraceptive in
the last six months (ORadj = 1.67, 95%CI: 1.09-2.54) had a higher risk to be infected; women living with their partner
had a lower risk (ORadj = 0.56, 95%CI: 0.34-0.92) to acquire infection than women living with parents/friends/alone.
Among HC2 positive women, HPV16 was the most prevalent type (30.9%), followed by 31 (19.6%), 66 (12.9%), 51
(11.3%), 18 (8.8%), 56 (8.8%). Co-infections of HR-HC2 targeted types were found in 20.4% of positive samples. The
HR-HPV prevalence in women with abnormal cytology (52.4%) was significantly higher than in women with normal
cytology (14.6%); however 33.0% of HR-HPV infected women had an abnormal cytology.
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Conclusion: HR-HPV prevalence in Italian women aged 18–26 years was 19%, higher than what detected for older
women, by other studies using the same molecular method and laboratory network; this result supports the choice
of electing girls before the sexual debut as the primary target of HPV vaccination. The HPV type distribution found
in this study may represent a baseline picture; an accurate post-vaccine surveillance is necessary to early detect a
possible genotype replacement. The high prevalence of viral types other than vaccine-HPV types supports the
necessity to guarantee the progression of CC screening programmes in vaccinated women.
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Background
In the last decade many studies have shown that infec-
tion with high-risk (HR) types of human papillomavirus
(HPV) is a necessary condition for the development of
invasive cervical cancer (CC) [1]. Genital HPV infection
is very common in sexually active women and is transi-
ent in most cases; only women with persistent infection
by HR-HPV types are likely to develop a cervical lesion
[2]. These findings led to the development of prophylac-
tic vaccines targeted to provide protection against
HPV16 and 18, responsible for the 70% of all cervical
cancers; efficacy has been shown to be highest in sub-
jects naïf to the infection [3,4].
As of July 2010, 18 European countries had integrated
HPV vaccination in their national immunization pro-
grammes, most of them targeting pre-adolescent girls;
nine countries had also planned catch up programmes
for older girls [5]. In Italy HPV vaccination is included
in the national immunization program and is offered to
11 year-old girls since 2007 [6]; six of the 21 Italian
Regions have also extended the offer to one older birth
cohort (varying by Region between 15–18 years), and
one Region to three cohorts (15, 18 and 24 year-old) [7].
Pre-vaccination distribution of HPV genotypes in target
populations is essential for designing, monitoring and
evaluating immunization strategies. Baseline prevalence is
relevant to estimate vaccine effectiveness against the
HPV-vaccine types, to evaluate the cross-protection of the
vaccines, and to monitor over time the relative frequency
of genotypes under the selective pressure of the vaccines.
Data on HPV prevalence in Italy are available for women
over the age of 24 years [8-10], target of the population-
based CC screening programmes. On the contrary there is
very limited amount of data on HPV prevalence in younger
ages [11,12]. The present study enrolled Italian women
aged 18–26 years in order to assess the prevalence of HR-
HPV types and detect the prevalent genotypes. Risk-factors
correlated with HR-HPV positivity were also described.
Methods
Study design and study population
This cross-sectional study was carried out in the period
2007–2009, coordinated by the Istituto Superiore di
Sanità (ISS, Italy’s National Institute of Public Health)
and partially sponsored by the Ministry of Health. It was
part of a national project (PreGio), which also included a
KAP (knowledge-attitudes-practices) survey on HPV in-
fection and CC prevention [13] and a study to estimate
the acceptance rate of HPV vaccination [14] .
A sample of 2,289 women was randomly selected from
the resident population lists of ten Local Health Units
(LHU) located in six Italian Regions scattered across the
country: Abruzzo and Campania in southern Italy
(1,026), Lazio and Tuscany in central Italy (388) and
Emilia-Romagna and Piedmont in northern Italy (875).
Both rural and urban LHUs were involved; all 10 LHUs
have population-based CC screening programmes.
The inclusion criteria for the study were: women aged
between 18 and 26 years and living in the selected
LHUs. Pregnant women and women who did not speak
Italian were excluded. The women were stratified into
two age groups (18–24 and 25–26 years), partially over-
lapping (25–26 years) with the target age of population-
based CC screening. Procedures for enrolling partici-
pants as well as study methodology have already been
described [13,14].
All women were offered Pap-test and HPV test; a writ-
ten informed consent was obtained by each participant.
Selected midwives, especially trained for this study, were
in charge of contacting sampled women, collecting
socio-demographic data and information regarding sex-
ual and reproductive history, getting informed consent
and performing cervical smears. The study was approved
by the national ethics committee of the ISS.
Cytology
Cervical smears were taken according to the consolidate
CC-screening procedures at the LHU. In most Regions
(Tuscany, Piedmont, Emilia-Romagna, Lazio, Campania)
two cervical samples were taken: one for Pap-test and
one for the HPV test in Specimen Transport Medium
(STM, DNAPAP cervical sampler, Qiagen, Gaithersburg,
USA); for STM sample, cytobrush was used to obtain
samples. In Abruzzo Region the cervical cell speci-
mens were put in PreservCyt solution (Hologic, Inc.,
Marlborough, MA) and used both for HPV testing and
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for cytological examination; for Preservcyt sample, Ayre
spatula and cytobrush were used. The cytology was
interpreted locally according to Bethesda 2001 system
[15]. Information on reproductive, sexual and cervical
screening history were collected (Table 1).
Women aged 25–26 years followed the routine proto-
col of treatment or follow-up according to cytological
results. A specific protocol for 18–24 year-old women
was adopted: colposcopy was offered to women with
HSIL (high squamous intraepithelial lesions) and ASCH
Table 1 Characteristics of the study population
Characteristics n (%) N
Socio-demographic characteristics
Mean age (years) 23.8 ± 0.07 * 1,094
Age group 18–24 years 598 (54.7) 1,094
25–26 years 496 (45.3)
Geographical area of residence North 445 (40.7) 1,094
Centre 235 (21.5)
South 414 (37.8)
Nationality Foreign 69 (6.3) 1,092
Italian 1,023 (93.7)
Educational level Low (≤8 years) 216 (19.8) 1,090
High (>8 years) 874 (80.2)




Marital status Single 974 (89.3) 1,091
Married 113 (10.3)
Divorced 4 (0.4)




Sexual behaviour and reproductive history
Mean age at first sexual intercourse (years) 17.5 ± 0.1 * 1,089
Parity 0 988 (90.4) 1,093
≥1child 105 (9.6)
Mean age at first delivery (years) 21.7 ± 0.3 * 105
No. of lifetime partners 1 377 (34.6) 1,091
2–4 558 (51.1)
≥5 156 (14.3)




Use of contraceptives in the last 6 months Yes 762 (74.5) 1,023
No 261 (25.5)
Use of condoms in the last 6 months Always 346 (33.9) 1,020
Rarely 307 (30.1)
Never 369 (36.0)
Previous Pap-test Yes 420 (38.5) 1,091
No 671 (61.5)
* (mean ± Standard Error).
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(atypical squamous cells that cannot exclude high-grade
lesions), while women with LSIL (low squamous intrae-
pithelial lesions) or less severe lesions were invited to re-
peat pap-test two years later and colposcopy was offered
only if, after two years, the diagnosis was still LSIL or it
progressed to a more severe lesion.
HPV testing
The HPV test was performed using Hybrid Capture 2
(HC2 High-Risk HPV DNA, Qiagen; Hilden, Germany)
according to the manufacturer’s instructions. It is a
hybridization assay which detects the presence of HPV-
DNA using cocktails of RNA probes and an amplified,
chemiluminescent signal. The high-risk group of probes
B, designed to detect HPV types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59 and 68, was used. The assay is cali-
brated on a positive cut off (pc) of 1 pg/ml of HPV-
DNA. Samples were considered positive when the ratio
between the Relative Light Units (RLU) of specimen and
the pc attained or exceeded the value of 1.0.
A regional laboratory was identified in Tuscany,
Piedmont, Abruzzo and Emilia-Romagna Regions for per-
forming HPV testing; the Analytical and Biomolecular
Cytology Unit of the Cancer Prevention and Research
Institute (ISPO) in Tuscany also analysed samples from
Campania and Lazio Regions.
Genotyping
Genotyping was performed on HR-HC2 positive sam-
ples. DNA was extracted using the QIAamp DNAMini
kit (Qiagen) according to the manufacturer’s instruc-
tions. For PreservCyt™ samples the elution volume varied
from 80 to 100 μl depending on the size of the pellet,
while for STM samples 100 μl of elution buffer (Buffer
AE) were used. To facilitate a higher recovery of DNA a
double elution was done for all the samples. HR-HC2
positive samples were typed using the “Consensus High
Risk HPV genotyping” kit assay (Digene Corporation,
Gaithersburg, USA). The test is based on the reverse
hybridization principle. Denaturated biotynilated ampli-
cons, resulting from the amplification of a part of the L1
region with GP5+/GP6+ primers, were hybridized with
specific oligonucleotide probes, which were immobilized
as parallel lines on membrane strips (Reverse Line Blot
Hybridization). The hybrids were detected with alkaline
phosphatase–streptavidin conjugate and substrate (5-
bromo-4-chloro-3-indolylphosphate and nitroblue tetra-
zolium), resulting in a purple precipitate at positive
probe lines. The kit allows the identification of 18 HPV
types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59,
66, 68, 73, 82). One HPV-positive control and two
negative PCR controls (a purified DNA sample negative
for HPV and a DNA free sample) were included in
each PCR run and subsequent Reverse Line Blot (RLB).
GP5+/GP6+ PCR-negative and RLB-negative samples
were amplified for the β-globin gene sequence using
GH20-PC04 primers (268-bp amplicon length) to assess
DNA integrity (Bauer).
The molecular Laboratory of ISPO performed geno-
typing of samples collected in all Italian regions involved
in the study except samples collected in Piedmont
Region, which were genotyped at the Center for Expe-
rimental Research and Medical Science of the Turin
University. ISPO also coordinated the molecular activ-
ities of the whole project, standardizing the procedures
for storing and analysing the samples according to a
protocol defined to guarantee the quality of molecular
methods [16].
Statistical analysis
Categorical variables were summarized by absolute fre-
quencies and percentages, and continuous variables by
means and Standard Error (SE). The Chi-square test and
Fisher’s exact test were used to compare proportions;
the t-test or Mann–Whitney nonparametric test was
used to compare continuous variables. Crude and
adjusted odds ratios (OR) and 95% confidence intervals
(95%CI) were calculated to evaluate the association be-
tween the HR-HPV positivity and socio-behavioural
characteristics.
Confounding was assessed by a multivariate logistic re-
gression approach; all variables with a p-value ≤0.15 in
the univariate analysis were included in the multivariate
model and retained in the final model according to a
log-likelihood-ratio test for goodness-of-fit. Statistical ana-
lysis was performed using STATA 11.2 (Stata Corporation,
College Station, Texas, USA).
Results
Study population
Recruitment was performed in the period ranging from
February 2008 to April 2009. The initial sample included
2,289 women; 239 did not meet the inclusion criteria
(124 did not live in the selected LHU, 57 were pregnant,
45 were not included in the 18–26 years range of age
and 13 did not speak Italian) and were replaced, and 290
could not be contacted. Thus 1,999 women were offered
Pap test and HPV test. Among them, 897 (44.9%)
declined participation for several issues (non interested
in the study, practical constraints, health disorders,
HPV-positivity, recent previous Pap-test, embarrass-
ment, parental advice, safety concerns, no sexual activ-
ity) (Figure 1). Women who did not participate were
slightly younger than participants (mean age 23.2 ± 0.09
vs. 23.9 ± 0.07 years; p < 0.001); the proportion of women
with a lower education level (24.6% vs 19.9%; p = 0.017),
living with parents (87.9 vs 74.6%; p = 0 < 001), unmar-
ried (93.5 vs 89.5%; p = 0.003) and living in southern
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Italy (53.3% vs 38.0%; p < 0.001) was higher in the group
of women who refused to participate.
In conclusion a total of 1,102 out of 2,289 women
(48.1%) were enrolled in the study. In order to calculate
the participation rate to the prevalence study, we consid-
ered more appropriate to exclude from the denominator
(2,289) the 154 women (among the 897 women who
declined participation) who spontaneously declared not
to be sexually active: therefore the participation rate was
51.6% (1,102/2,135), with a range among LHUs of 23.9-
80.7.
The mean age of participants was 23.8 ± 0.07 years;
40.7% lived in northern Italy, 37.8% in southern Italy,
and 21.5% in central Italy. Most women were Italian
(93.7%), unmarried (89.3%) and had a high educational
level, defined as > 8 years of education (80.2%). Detailed
socio-behavioural characteristics are shown in Table 1.
HPV prevalence and genotyping
The Pap-test was performed on 1,099 cervical smears
because three samples were missed (they were included
in the CC screening programme, instead of being
included in the PreGio study) and the HR-HPV testing
was performed on 1,094 out of 1,999 samples (the ma-
terial of five samples was not sufficient for HR-HC2
test). The proportion of HR-HC2 positive samples was
18.7% (205/1,094) and did not differ by geographic area
and age group (Table 2).
The genotyping was performed on 202/205 HR-HPV
positive samples (three samples were not adequate be-
cause material was not sufficient for genotyping) and
194 (96%) showed positivity at least for one of the 18
types identifiable by the kit assay used for genotyping. In
contrast, eight samples (4%) did not result positive at
any of these 18 types: this proportion is in line with data
reported in literature [17,18] and is mainly due to the
cross-reactivity of the probe B with low-risk HPV types.
Among Hybrid Capture positive women HPV16 was
the most prevalent type (30.9%), followed by 31 (19.6%),
66 (12.9%), 51 (11.3%), 18 (8.8%), 56 (8.8%) and 58
(8.3%); all the other types were detected at frequencies
lower than 5.2% (Table 3); the cumulative rate of 16 and
18 was 38.7%.
The prevalence of HPV 26, 53, 66, 73, 82 is underesti-
mated because these HPV types are detected by the
“Consensus High Risk HPV genotyping” assay, but they
are not targeted by HR-HC2 test; the detection of HPV
26, 53, 66, 73, 82 is due to an occasional cross-
hybridization of HR-HC2 method or co-infection with
HPV-targeted types, therefore they could more likely ap-
pear in multiple than single infections. For this reason
we limited the analysis of multiple infections to the 13
HR-HPV types targeted by HR-HC2 test.
Out of 181 women infected by HR-HC2 targeted
types, 37 (20.4%) had a multiple infection (36 infected
by two types and one by three types). No difference in
socio-demographic characteristics and sexual and repro-
ductive history was found between women presenting a
multiple and single infection. HPV16 was the most com-
mon genotype detected in multiple infections, followed
by HPV31 and 18. Table 4 shows the distribution of
HPV types in single and multiple infections; the propor-
tion of single and co-infections by genotype is also
reported: the proportion of infections occurring in con-
junction with other types did not significantly differ by









































Figure 1 Study population. *Not traced: women who were not traced although three phone calls and two home visits. **Not eligible: women
who did not meet inclusion criteria and were replaced with women of the same age group and local health unit. ***Declined participation:
women who were contacted and met the inclusion criteria, but refused to participate in the prevalence study. ‡Un-typeable samples: HR-HC2
positive samples that resulted negative at any of the 18 types identifiable by the kit assay used for genotyping.
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Determinants of high risk HPV prevalence
The univariate analysis of socio-behavioural characteristics
and HR-HPV infection is reported in Table 2. The risk of
HR-HPV infection resulted significantly higher in women
who declared a greater number of partners in lifetime
(OR = 3.78, 95%CI: 2.40-5.94 if 2–4 partners and OR =
9.29, 95%CI: 5.54-15.57 if ≥5 partners) and in the last six
months (OR = 2.96, 95%CI 1.73-5.07 if ≥2 partners), and
in women who have used any contraceptive method in the
last six months (OR = 1.70, 95%CI 1.14-2.53). In contrast,
the risk of HR-HPV infection resulted significantly lower
in women living with their partner compared to women
living with parents/friends/alone (OR = 0.53, 95%CI: 0.33-
0.86), in married women (OR = 0.30, 95%CI: 0.14-0.63)
and women with children (OR = 0.43, 95%CI: 0.22-0.84).
Also a higher age at the first intercourse showed a protect-
ive effect (OR = 0.92, 95%CI: 0.85-0.99).
The following variables were included in the multivari-
ate model: marital status, “living with”, age at first sexual
intercourse, age at first delivery, parity, number of life-
time partners, number of partners in the last six months,
use of contraceptives in the last six months.
Table 2 Determinants of HR-HPV prevalence: univariate (OR crude) and multivariate (OR adj) logistic regression
analysis
Characteristics HR-HPV positivity Univariate analysis Multivariate model**
n/N (%) OR crude 95%CI OR adj 95%CI
Age Group 18-24 years 119/597 (19.9) 1 -
25-26 years 86/496 (17.3) 0.84 (0.62 – 1.14)
Geographical area of residence Centre 44/235 (18.8) 1 -
North 86/445 (19.3) 1.03 (0.69 – 1.55)
South 75/414 (18.1) 0.95 (0.63 – 1.44)
Nationality Foreign 13/69 (18.8) 1 -
Italian 192/1023 (18.7) 0.99 (0.53 – 1.86)
Educational level Low (≤8 years) 39/216 (18.1) 1 -
High (>8 years) 166/874 (19.0) 1.06 (0.72 – 1.56)
Employment status Student 79/455 (17.4) 1 -
Employed 80/415 (19.3) 1.14 (0.80 – 1.60)
Other 45/214 (21.0) 1.27 (0.84 – 1.91)
Marital status Single 197/974 (20.2) 1 -
Married 8/113 (7.1) 0.30 (0.14 – 0.63)
Lives with Parents/friends/alone 182/904 (20.1) 1 - 1 -
Partner 22/185 (11.9) 0.53 (0.33 – 0.86) 0.56 (0.34 - 0.92)
Mean age at first sexual intercourse (years) * 17.2 0.92 (0.85 – 0.99)
Parity 0 195/988 (19.7) 1 -
≥ 1 child 10/105 (9.5) 0.43 (0.22 – 0.84)
Mean age at first delivery (years) * 21.8 1.01 (0.78 – 1.30)
No. of lifetime partners 1 25/377 (6.3) 1 - 1 -
2-4 118/558 (21.1) 3.78 (2.40 – 5.94) 4.15 (2.56 – 6.72)
≥5 62/156 (39.7) 9.29 (5.54 – 15.57) 10.63 (6.16 – 18.36)
No. of partners in the last 6 months 0-1 181/1031 (17.6) 1 -
≥2 24/62 (38.7) 2.96 (1.73 – 5.07)
Use of contraceptives in the last 6 months No 35/261 (13.4) 1 - 1 -
Yes 159/762 (20.9) 1.70 (1.14 – 2.53) 1.67 (1.09 – 2.54)
Use of condoms in the last 6 months Always 68/346 (19.7) 1 -
Rarely 65/307 (21.2) 1.10 (0.75 – 1.60)
Never 61/367 (16.6) 0.81 (0.56 – 1.19)
Previous Pap-test No 135/671 (20.1) 1 -
Yes 70/420 (16.7) 0.79 (0.58 – 1.09)
*mean.
**The following variables have been included in the multivariate model: marital status, living with, mean age at first sexual intercourse, mean age at first delivery,
parity, number of lifetime partners, number of partners in the last 6 months, use of contraceptives in the last 6 months.
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In the multivariate logistic regression model (Table 2),
the effect of the number of lifetime sexual partner
remained statistically significant (ORadj = 4.15, 95%CI:
2.56-6.72 if 2–4 partners and ORadj = 10.63, 95%CI: 6.16-
18.36 if ≥5 partners). Also, living with the sexual partner
and having used any contraceptive in the last six months
remained significantly associated with the detection of
HR-HPV infection (ORadj = 0.56, 95%CI: 0.34-0.92 and
ORadj = 1.67, 95%CI: 1.09-2.54 respectively).
Cytology
The pap-test result was available for 1,093/1,094 cervical
smears tested for HR-HC2; 5.7% (62/1,093) of samples
were inadequate, cytology was normal in 83.0% samples
(907/1,093) and abnormal in 11.3% (124/1,093) samples:
62 ASCUS/AGUS (atypical squamous/glandular cervical
cells of undetermined significance), 52 LSIL, 6 ASCH
and 4 HSIL. The proportion of HR-HPV positivity was
significantly higher in women with abnormal cytology
(65/124, 52.4%) than in women with normal cytology
(132/907, 14.6%) (p < 0,001). Among the 197 HPV-
infected women with adequate cytology, 65 (33.0%) had
an abnormal finding.
HPV16 was the most frequent virus strain in normal
cytology, ASCUS/AGUS, LSIL and ASCH, detected in
29.3, 47.8, 24.2 and 66.7% of the samples respectively.
All the four HSIL were HR-HPV positive and four differ-
ent types were detected respectively (16, 18, 31, 33).
Discussion
We found a prevalence of HR-HPV infections of 19% in
a sample of Italian women aged 18–26 years. This per-
centage is in agreement with an Italian study which used
a similar methodology to measure the HR-HPV preva-
lence in 18–24 year-old women from Tuscany Region
[11]. This value is also included within the range (20-
45%) reported in other national or worldwide studies for
women younger than 25 years [12,19-22], although it is
difficult to compare results of different studies because
of different age groups and different procedures for en-
rolling participants. Not surprisingly, the rate of infec-
tion in this age group was higher than what was found
in women aged 25–29 (14%) in New Technologies for
CC screening (NTCC) randomized trials, which studied
45,000 women aged 25–60 years of northern and central
Italy, participating in CC screening programmes [8,9].
This finding reflects a higher probability of acquiring
new infections at younger ages, confirming the trend
described in the international literature with a peak of
HR-HPV prevalence in younger women and a continu-
ous decline with increasing age [19-22].
Table 3 Distribution of HPV genotypes in HR-HC2 test







(N = 194), %
Overall
population*
(N = 1094), %
16 60 30.9 5.5
31 38 19.6 3.5
66** 25 12.9 2.3
51 22 11.3 2.0
18 17 8.8 1.6
56 17 8.8 1.6
58 16 8.3 1.5
59 10 5.2 0.9
52 9 4.6 0.8
39 9 4.6 0.8
45 8 4.1 0.7
53** 7 3.6 0.6
33 6 3.1 0.5
68 6 3.1 0.5
73** 3 1.5 0.3
35 2 1.0 0.2
82** 1 0.5 0.1
26** 0 0.0 0.0
* HPV type-specific prevalence has been extrapolated to overall population
although it should be stressed that the genotyping was performed only on
HR-HC2 positive samples.
** The prevalence of HPV 26,53,66,73,82 is probably underestimated because
these HPV types are detected by the “Consensus High Risk HPV genotyping”
assay, but they are not targeted by the HR-HC2 test.
Table 4 Distribution of HPV genotypes in single/multiple




Single infections Multiple infections
n %** n %**
16 43 71.7 17 28.3
31 21 55.3 17 44.7
51 16 72.7 6 27.3
18 7 41.2 10 58.8
56 12 70.6 5 29.4
58 11 68.7 5 31.3
59 6 60.0 4 40.0
52 5 55.6 4 44.4
39 6 66.7 3 33.3
45 7 87.5 1 12.5
33 3 50.0 3 50.0
68 6 100.0 0 0.0
35 1 50.0 1 50.0
All 144 65.5 76 34.5
* All genotypes from single and multiple infections were
computed individually.
** The denominator is represented by the total number of infections (single
plus multiple) by genotype.
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Cervical cancer incidence is lower in the South than in
the North of Italy, therefore a lower HR-HPV prevalence
in the general population was expected in the South.
Instead, we did not find any difference in HR-HPV
prevalence rates between northern, central and southern
regions of Italy, confirming what reported by Agarossi
and coll. [22]. This finding should encourage the imple-
mentation, strengthening and promotion of cervical can-
cer screening programmes in southern Italy, where
coverage and acceptance are still lower than in the rest
of the country [23].
Genotype HPV16 was detected in 31% of HR-HC2
positive samples, followed by 31, 66, 51 and 18. This is
well consistent with the results of a comprehensive
meta-analysis on HPV positive women with normal cy-
tology conducted by de Sanjosé and coll. [24], which
reported HPV16, 31 and 18 among the five most com-
mon types worldwide. In Italy, HPV16 resulted to be the
genotype most frequently detected in all studies and
HPV 31 was frequently reported as the second most
common genotype [11,22,25,26]. Regarding the other
genotypes a high variability is reported among studies,
which could be due to geographical differences, different
target populations, different methods for genotyping and
random fluctuation for quite rare genotypes [27,28].
According to the International Agency for Research
on Cancer (IARC) classification, HPV16, 31, 51 and 18
are classified as “carcinogenic to humans”, while HPV
66 is classified as “possibly carcinogenic” [29]. It should
be also mentioned that the prevalence of HPV 66, as of
the other genotypes not targeted by HR-HC2 (HPV 53,
26, 73, 82), observed in the present study is plausibly
underestimated because the detection of these types is
only due to an occasional cross-hybridization of the
method or co-infection with HPV-targeted types.
As expected, we found that women with cervical cyto-
logical abnormalities were at significantly increased risk
for being infected by HR-HPV types than women with
normal cytology (52 vs. 15%). Current Italian studies in-
volving women with cytological abnormalities (different
ages and enrolment criteria) reported HR-HPV prevalence
of 34-68%, increasing with cytology severity: 24-56% in
case of diagnosis of ASCUS/AGUS, 42-72% in LSIL and
73-95% in HSIL [21,22,26,27,30-32].
Co-infections of HR-HC2 targeted types represented
the 20% of HPV positive samples. This value is included
in the range (15-50%) reported in literature [33]; similar
percentages of single and multiple HPV infections have
been observed in young general populations [34,35]. It is
still not clear whether co-infection with multiple types
increases the risk of progression to cancer [22,36].
The multivariate analysis evidenced the role of the num-
ber of lifetime sexual partners as determinant of HPV
infection, consistently with other studies [11,12,21,37],
and strengthens the concept that that the most suitable
age for HPV vaccination is the period preceding sexual ac-
tivity. Living with partner had a protective effect against
HR-HPV infection in the multivariate model; consistently
with another Italian study [38], being married and having
children showed a protective effect in the crude analysis,
although not statistically significant in the multivariate
analysis. All these variables could be considered markers
of a steady relationship, explaining the association with a
low HR-HPV prevalence. The use of any contraceptive
method in the last six months remained associated to HR-
HPV infection in the final model; we could suppose that
women who used contraceptives in the last six months
could have had a more intense sexual activity, with a
higher risk of acquiring HPV, whose prevalence is higher
in young ages. If considering only the use of condoms in
the last six months, no association was detected between
HR-HPV prevalence and this method of contraception;
this point is debated and conclusions about the associ-
ation between condoms’ use and HR-HPV prevalence are
discordant among authors [11].
The major strengths of this study are that the sample
was large and it targeted an age group that has not been
investigated extensively.
Among the limitations, it should be mentioned the
fact that our sample may not be entirely representative
of Italy’s general population of females aged 18–26 years
because only ten LHUs in six Regions participated,
though local probabilistic samples were population-
based and both urban and rural LHUs in northern, cen-
tral and southern Italy were involved.
In addition the participation rate was 52%, therefore
our findings could not be representative of the entire stu-
dy population; however differences in socio-demographic
characteristics between participants and people who de-
clined participation were minimal.
The participation rate could be underestimated be-
cause we have excluded from the initial sample the 154
women who spontaneously declared not to be sexually
active, but we do not know if other women, who
declined participation, were virgin too (we did not col-
lect this information). This age group represents a diffi-
cult target for prevention measures, because in Italy
young adult women are not accustomed to being targeted
by preventive programmes; moreover, enrolled women
were offered the participation to a package of activities
within the PreGio project, which is more difficult to be
accepted than a single cervical smear. On the other hand,
it should be noted that the study personnel had received
special training and that a high number of attempts were
made to contact non-respondents. Two other studies
[11,12], which detected HPV prevalence of a sample of
Italian women aged 18–24 years randomly selected
from population registries, got a lower participation rate
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(15-22%). In these two studies letters of invitation were
mailed to sampled women and a reminder was sent in
case of no response, whereas we planned three phone calls
and two home visits for non respondents.
As already mentioned, another limitation is that the
prevalence of HPV 26, 53, 66, 73 and 82 could be heavily
underestimated because they are not targeted by HR-
HC2 test. In fact HPV 73 and 82 were observed only in
co-infection with other HR-HPV types, suggesting that
they could have been found only because coexisted with
HPV types detected by HR-HC2 probes B (for this
reason we excluded HR-HC2 not targeted types from
the analysis of co-infections).
Conclusion
We measured the genital HR-HPV prevalence in Italian
women aged 18–26 years before the introduction of
HPV vaccination across all the areas of Italy; we found a
prevalence of 19%, higher than what detected for older
women [19-22]. The use of the same molecular method
and laboratory network of the NTCC studies [8,9],
targeting women aged 25–60 years, allowed us to depict
a comprehensive picture of HR-HPV prevalence in Italy
from 18 to 60 years of age, observing in young adult
women a peak of prevalence, which drops with increasing
age. The findings support the choice of electing girls before
the sexual debut as the primary target of HPV vaccination.
The HPV type distribution found in this study may rep-
resent a baseline picture; an accurate post-vaccine surveil-
lance is, in fact, necessary to early detect a possible
genotype replacement. The high prevalence of viral types
other than vaccine-HPV types supports the necessity to
guarantee the progression of CC screening programmes in
vaccinated women. Studies linking screening programmes
with vaccine immunization registries should be performed
to evaluate the HPV vaccine effectiveness on vaccine-
related and not-vaccine related types.
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